Actelion included in the Swiss Market Index SMI

Monday, 22. September 2008 07:00
Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




ALLSCHWIL/Basel, SWITZERLAND - 22 September 2008 - Actelion Ltd (SWX:
ATLN) announced that, as of today, Monday 22 September 2008, its
shares (ATLN, CH001053247) will start trading as part of the Swiss
Market Index SMI®, the Swiss blue-chip index.

Jean-Paul Clozel, M.D. and Chief Executive Officer commented: "In
just eight years following Actelion's initial listing on the Swiss
Stock Exchange, our ability to create growth and subsequent long-term
shareholder value has been recognized by today's inclusion of our
shares in the SMI®. We are proud to be part of a stock market index,
which includes some of the best companies in the world. For Actelion,
this inclusion is a milestone in our short history and an inspiration
to continue the discovery, development and marketing of innovative
medicines that have the potential to change patients' lives."

As a blue-chip index, the SMI® is Switzerland's key equity index. It
represents about 85% of the free-float capitalization of the Swiss
equity market. The index comprises the 20 largest and most liquid
equities of the SPI® (Swiss Performance Index®). Since the SMI® is
considered to be a mirror of the overall Swiss stock market, it is
used as the underlying index for numerous derivative financial
instruments such as options, futures and index funds (e.g. ETFs). The
composition of the index is examined - and - if appropriate - updated
once a year. More details about the SMI® index are available on the
SWX Swiss Exchange website at www.swx.com

###

Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate
headquarters in Allschwil/Basel, Switzerland. Actelion's first drug
Tracleer®, an orally available dual endothelin receptor antagonist,
has been approved as a therapy for pulmonary arterial hypertension.
Actelion markets Tracleer® through its own subsidiaries in key
markets worldwide, including the United States (based in South San
Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in
innovative science related to the endothelium - the single layer of
cells separating every blood vessel from the blood stream. Actelion's
over 1700 employees focus on the discovery, development and marketing
of innovative drugs for significant unmet medical needs. Actelion
shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI® )

For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
http://www.actelion.com

Upcoming Corporate Events


+-------------------------------------------------------------------+
| Tuesday 21 October, 2008 | 9-months 2008 results: |
| | -Update on development pipeline |
| | (webcast only) |
| | |
|--------------------------+----------------------------------------|
| Thursday February 19, | Actelion Day, Allschwil / Switzerland: |
| 2009 | -Full Year 2008 results |
| | -Research & Development presentations |
| | -Tour of Actelion's Research |
| | facilities |
+-------------------------------------------------------------------+


The Sleep 101 educational event has been moved to 2009.



--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil
Switzerland

WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP,
SMIM, SPI, SPIEX;
Listed: Main Market in SWX Swiss Exchange;

View document
Related Links: Actelion Pharmaceutical Ltd
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.